![]() |
Blood Cancer TalksThis is a podcast on latest advances in the understanding and management of blood cancers. Author: Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth. Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk Language: en Genres: Education, Health & Fitness, Medicine Contact email: Get it Feed URL: Get it iTunes ID: Get it Trailer: |
Listen Now...
Episode 76. IMS 2026 Roundup with Dr. Manni Mohyuddin
Episode 77
Friday, 6 November, 2026
Episode summary In this episode, we bring Dr. Manni Mohyuddin from Huntsman Cancer Center [Utah] to go through the biggest myeloma data from the 2026 International Myeloma Society (IMS) Annual Meeting at Glasgow. In this episode1. CERVINO (Phase 3): Etentamig vs. standard therapy in triple-class-exposed RRMMPatients had at least 2 prior lines, were triple-class exposed and had no prior BCMA therapy. They were randomized to etentamig or the investigator’s choice of Kd, EPd or SVd. The co-primary endpoints were ORR and PFS.Etentamig is dosed every 4 weeks from the start, and patients in CR could stop after 2 years.The population was more heavily pretreated than MajesTEC-9: 51% were triple-class refractory (vs. about 30%), with a median of 3 prior lines.Discussion: Where CERVINO fits with MajesTEC-3 and MajesTEC-9Efficacy compared with teclistamab, elranatamab and linvoseltamabWhether low-affinity CD3 binding really means less CRSInfection risk2. EXCALIBUR-RRMM (Phase 3): Iberdomide-Dara-Dex vs. DVdThe trial enrolled patients with relapsed myeloma that was not refractory to anti-CD38 therapy. About 70% had 1 prior line, about 90% had prior IMiD exposure and about 40% were IMiD-refractory. Iberdomide was given at 1 mg, the dose chosen in stage 1.The dual primary endpoints both favored the iberdomide arm: MRD-negative CR: 41% vs. 21%Median PFS: 42 vs. 20 monthsDiscussion: How this compares with MajesTEC-3 and DREAMM-7 in a similar populationWhere IberDd may fit in practice: as a bridge before CAR-T, or for indolent or biochemical relapse in patients whose disease isn’t dara-refractoryWhether the more selective CELMoD design means fewer non-hematologic side effects than lenalidomide-based triplets3. GEM-TECTAL (Spanish Myeloma Group): MRD-guided Tec-Dara and Tal-Dara in high-risk NDMMThe schema: 4 cycles of Dara-VRdStem cell collection and MRD assessment6 cycles of Tec-Dara consolidationNext step by MRD status: patients who are MRD-negative get 2 years of Tec-Dara maintenance, and patients who are MRD-positive get early rescue with 6 cycles of Tal-Dara.63% of patients were high-risk by the IMS-IMWG definition.MRD negativity at 10⁻⁶ by NGF was 40% after Dara-VRd and 86% after Tec-Dara consolidation. Only 1 patient was still MRD-positive.Discussion: the safety of Tec-Dara consolidation, and whether this will be the next frontier for high-risk disease4. TRILOGY-1: Updated Phase 1 data for ramantamig (BCMA×GPRC5D trispecific)The patients were heavily pretreated: Median of 3 prior lines100% triple-class exposed and 50% triple-class refractory96% CD38-refractory14% with prior BCMA therapyDosing is every 4 weeks from the start, moving to every 8 weeks after 6 months.In BCMA/GPRC5D-naïve patients, the CR rate was about 80%, and 90% of those CRs were MRD-negative at 10⁻⁶. 2-year PFS was 81%, and about 85% in the original cohort with 26 months of follow-up.Grade ≥3 infections occurred in 25% of patients, which is lower than in MajesTEC-9 at similar follow-up and may reflect more routine primary IVIG prophylaxis.Skin, nail and oral side effects were milder than with talquetamab, and mean weight loss was under 5%.












